Healthcare Feb 16, 2023 12:51 PM (GMT+8)
Rezu Bio (Chinese: 宁康瑞珠) announced the close of a CNY 10 million Series Pre-A funding round, which was led by Riverhead Capital (Chinese: 阳光融汇资本). Riemann Hypothesis (Chinese: 黎曼猜想) acted as the exclusive financial adviser. Proceeds raised in this round will be mainly used in platform building and the promotion of product pipeline development. Rezu Bio has developed a brand-new colon-restricted drug design platform with completely independent intellectual property rights, which can help companies obtain multiple compounds targeting colon targets. Since designed compounds mainly act on local tissues or organs, which can avoid toxic side effects caused by systemic circulation, thereby are safer and more efficient.